{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:15:33Z","timestamp":1771535733891,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuronal loss alongside altered energy metabolism, are key features of Huntington\u2019s disease (HD) pathology. The orexigenic gut-peptide hormone ghrelin is known to stimulate appetite and affect whole body energy metabolism. Liraglutide is an efficient anti-type 2 diabetes incretin drug, with neuroprotective effects alongside anorectic properties. Combining liraglutide with the orexigenic peptide ghrelin may potentially promote brain\/cognitive function in HD. The R6\/2 mouse model of HD exhibits progressive central pathology, weight loss, deranged glucose metabolism, skeletal muscle atrophy and altered body composition. In this study, we targeted energy metabolism in R6\/2 mice using a co-administration of liraglutide and ghrelin. We investigated their effect on brain cortical hormone-mediated intracellular signalling pathways, metabolic and apoptotic markers, and the impact on motor function in HD. We here demonstrate that liraglutide, alone or together with ghrelin (subcutaneous daily injections of 150\u2009\u00b5g\/kg (ghrelin) and 0.2\u2009mg\/kg (liraglutide), for 2 weeks), normalized glucose homeostatic features in the R6\/2 mouse, without substantially affecting body weight or body composition. Liraglutide alone decreased brain cortical active GLP-1 and IGF-1 levels in R6\/2 mice, alongside higher ADP levels. Liraglutide plus ghrelin decreased brain insulin, lactate, AMP and cholesterol levels in R6\/2 mice. Taken together, our findings encourage further studies targeting energy metabolism in HD.<\/jats:p>","DOI":"10.1038\/s41598-018-27121-w","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T10:56:25Z","timestamp":1528282585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6\/2 Mouse Model of Huntington\u2019s Disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-7867","authenticated-orcid":false,"given":"Ana I.","family":"Duarte","sequence":"first","affiliation":[]},{"given":"Marie","family":"Sj\u00f6gren","sequence":"additional","affiliation":[]},{"given":"Maria S.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Catarina R.","family":"Oliveira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-6747","authenticated-orcid":false,"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Bj\u00f6rkqvist","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"27121_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"27121_CR2","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990\u20131993 (1997).","journal-title":"Science"},{"key":"27121_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","volume":"14","author":"JB Carroll","year":"2015","unstructured":"Carroll, J. B., Bates, G. P., Steffan, J., Saft, C. & Tabrizi, S. J. Treating the whole body in Huntington\u2019s disease. The Lancet. Neurology 14, 1135\u20131142, https:\/\/doi.org\/10.1016\/S1474-4422(15)00177-5 (2015).","journal-title":"The Lancet. Neurology"},{"key":"27121_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM van der Burg","year":"2009","unstructured":"van der Burg, J. M., Bjorkqvist, M. & Brundin, P. Beyond the brain: widespread pathology in Huntington\u2019s disease. The Lancet. Neurology 8, 765\u2013774, https:\/\/doi.org\/10.1016\/S1474-4422(09)70178-4 (2009).","journal-title":"The Lancet. Neurology"},{"key":"27121_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2011.05.006","volume":"44","author":"JM van der Burg","year":"2011","unstructured":"van der Burg, J. M. et al. Gastrointestinal dysfunction contributes to weight loss in Huntington\u2019s disease mice. Neurobiology of disease 44, 1\u20138, https:\/\/doi.org\/10.1016\/j.nbd.2011.05.006 (2011).","journal-title":"Neurobiology of disease"},{"key":"27121_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.410310202","volume":"31","author":"MF Beal","year":"1992","unstructured":"Beal, M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Annals of neurology 31, 119\u2013130, https:\/\/doi.org\/10.1002\/ana.410310202 (1992).","journal-title":"Annals of neurology"},{"key":"27121_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2174\/1389450111007011218","volume":"11","author":"TR Rosenstock","year":"2010","unstructured":"Rosenstock, T. R., Duarte, A. I. & Rego, A. C. Mitochondrial-associated metabolic changes and neurodegeneration in Huntington\u2019s disease - from clinical features to the bench. Current drug targets 11, 1218\u20131236 (2010).","journal-title":"Current drug targets"},{"key":"27121_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2010.06741.x","volume":"114","author":"JM Oliveira","year":"2010","unstructured":"Oliveira, J. M. Nature and cause of mitochondrial dysfunction in Huntington\u2019s disease: focusing on huntingtin and the striatum. Journal of neurochemistry 114, 1\u201312, https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06741.x (2010).","journal-title":"Journal of neurochemistry"},{"key":"27121_CR9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.25992","volume":"29","author":"W Duan","year":"2014","unstructured":"Duan, W., Jiang, M. & Jin, J. Metabolism in HD: still a relevant mechanism? Movement disorders: official journal of the Movement Disorder Society 29, 1366\u20131374, https:\/\/doi.org\/10.1002\/mds.25992 (2014).","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"27121_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","volume":"62","author":"A Johri","year":"2013","unstructured":"Johri, A., Chandra, A. & Beal, M. F. PGC-1alpha, mitochondrial dysfunction, and Huntington\u2019s disease. Free radical biology & medicine 62, 37\u201346, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.04.016 (2013).","journal-title":"Free radical biology & medicine"},{"key":"27121_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacl.2009.11.003","volume":"4","author":"RC Block","year":"2010","unstructured":"Block, R. C., Dorsey, E. R., Beck, C. A., Brenna, J. T. & Shoulson, I. Altered cholesterol and fatty acid metabolism in Huntington disease. Journal of clinical lipidology 4, 17\u201323, https:\/\/doi.org\/10.1016\/j.jacl.2009.11.003 (2010).","journal-title":"Journal of clinical lipidology"},{"key":"27121_CR12","first-page":"21","volume":"31","author":"A Montoya","year":"2006","unstructured":"Montoya, A., Price, B. H., Menear, M. & Lepage, M. Brain imaging and cognitive dysfunctions in Huntington\u2019s disease. Journal of psychiatry & neuroscience: JPN 31, 21\u201329 (2006).","journal-title":"Journal of psychiatry & neuroscience: JPN"},{"key":"27121_CR13","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3945\/jn.114.206029","volume":"145","author":"CC Ronveaux","year":"2015","unstructured":"Ronveaux, C. C., Tome, D. & Raybould, H. E. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. The Journal of nutrition 145, 672\u2013680, https:\/\/doi.org\/10.3945\/jn.114.206029 (2015).","journal-title":"The Journal of nutrition"},{"key":"27121_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1172\/JCI42497","volume":"122","author":"BJ Lamont","year":"2012","unstructured":"Lamont, B. J. et al. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. The Journal of clinical investigation 122, 388\u2013402, https:\/\/doi.org\/10.1172\/JCI42497 (2012).","journal-title":"The Journal of clinical investigation"},{"key":"27121_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/35038090","volume":"407","author":"M Tschop","year":"2000","unstructured":"Tschop, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908\u2013913, https:\/\/doi.org\/10.1038\/35038090 (2000).","journal-title":"Nature"},{"key":"27121_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson, G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. Journal of neuroscience research 86, 326\u2013338, https:\/\/doi.org\/10.1002\/jnr.21483 (2008).","journal-title":"Journal of neuroscience research"},{"key":"27121_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/db08-0799","volume":"58","author":"B Martin","year":"2009","unstructured":"Martin, B. et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease. Diabetes 58, 318\u2013328, https:\/\/doi.org\/10.2337\/db08-0799 (2009).","journal-title":"Diabetes"},{"key":"27121_CR18","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean, P. L., Parthsarathy, V., Faivre, E. & Holscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 31, 6587\u20136594, https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011 (2011).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"27121_CR19","first-page":"497","volume":"66","author":"C Holscher","year":"2014","unstructured":"Holscher, C. Drugs developed for treatment of diabetes show protective effects in Alzheimer\u2019s and Parkinson\u2019s diseases. Sheng li xue bao: [Acta physiologica Sinica] 66, 497\u2013510 (2014).","journal-title":"Sheng li xue bao: [Acta physiologica Sinica]"},{"key":"27121_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s12640-009-9037-x","volume":"15","author":"M Moon","year":"2009","unstructured":"Moon, M. et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease by blocking microglial activation. Neurotoxicity research 15, 332\u2013347, https:\/\/doi.org\/10.1007\/s12640-009-9037-x (2009).","journal-title":"Neurotoxicity research"},{"key":"27121_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2010-101263","volume":"23","author":"M Moon","year":"2011","unstructured":"Moon, M. et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomer-injected mice. Journal of Alzheimer\u2019s disease: JAD 23, 147\u2013159, https:\/\/doi.org\/10.3233\/JAD-2010-101263 (2011).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"27121_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ijo.2014.88","volume":"39","author":"TA Wadden","year":"2015","unstructured":"Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International journal of obesity 39, 187, https:\/\/doi.org\/10.1038\/ijo.2014.88 (2015).","journal-title":"International journal of obesity"},{"key":"27121_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/hmg\/ddi053","volume":"14","author":"M Bjorkqvist","year":"2005","unstructured":"Bjorkqvist, M. et al. The R6\/2 transgenic mouse model of Huntington\u2019s disease develops diabetes due to deficient beta-cell mass and exocytosis. Human molecular genetics 14, 565\u2013574, https:\/\/doi.org\/10.1093\/hmg\/ddi053 (2005).","journal-title":"Human molecular genetics"},{"key":"27121_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"},{"key":"27121_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diabetes care 27, 1487\u20131495 (2004).","journal-title":"Diabetes care"},{"key":"27121_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1074\/jbc.M111.309849","volume":"287","author":"F Mochel","year":"2012","unstructured":"Mochel, F. et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. The Journal of biological chemistry 287, 1361\u20131370, https:\/\/doi.org\/10.1074\/jbc.M111.309849 (2012).","journal-title":"The Journal of biological chemistry"},{"key":"27121_CR27","doi-asserted-by":"publisher","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","volume":"25","author":"M Valenza","year":"2005","unstructured":"Valenza, M. et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 9932\u20139939, https:\/\/doi.org\/10.1523\/JNEUROSCI.3355-05.2005 (2005).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"27121_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrn3228","volume":"13","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. & Yuan, J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nature reviews. Neuroscience 13, 395\u2013406, https:\/\/doi.org\/10.1038\/nrn3228 (2012).","journal-title":"Nature reviews. Neuroscience"},{"key":"27121_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cell.2010.03.053","volume":"141","author":"Z Li","year":"2010","unstructured":"Li, Z. et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 141, 859\u2013871, https:\/\/doi.org\/10.1016\/j.cell.2010.03.053 (2010).","journal-title":"Cell"},{"key":"27121_CR30","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature04724","volume":"441","author":"T Hara","year":"2006","unstructured":"Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885\u2013889, https:\/\/doi.org\/10.1038\/nature04724 (2006).","journal-title":"Nature"},{"key":"27121_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2013.02.017","volume":"23","author":"L Lamy","year":"2013","unstructured":"Lamy, L. et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer cell 23, 435\u2013449, https:\/\/doi.org\/10.1016\/j.ccr.2013.02.017 (2013).","journal-title":"Cancer cell"},{"key":"27121_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"JY Li","year":"2005","unstructured":"Li, J. Y., Popovic, N. & Brundin, P. The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics 2, 447\u2013464, https:\/\/doi.org\/10.1602\/neurorx.2.3.447 (2005).","journal-title":"NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"27121_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"27121_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.25007","volume":"82","author":"JMM van der Burg","year":"2017","unstructured":"van der Burg, J. M. M. et al. Body weight is a robust predictor of clinical progression in Huntington disease. Annals of neurology 82, 479\u2013483, https:\/\/doi.org\/10.1002\/ana.25007 (2017).","journal-title":"Annals of neurology"},{"key":"27121_CR35","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1371\/journal.pone.0000647","volume":"2","author":"F Mochel","year":"2007","unstructured":"Mochel, F. et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PloS one 2, e647, https:\/\/doi.org\/10.1371\/journal.pone.0000647 (2007).","journal-title":"PloS one"},{"key":"27121_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/brain\/awl027","volume":"129","author":"BR Underwood","year":"2006","unstructured":"Underwood, B. R. et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain: a journal of neurology 129, 877\u2013886, https:\/\/doi.org\/10.1093\/brain\/awl027 (2006).","journal-title":"Brain: a journal of neurology"},{"key":"27121_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2007.07.029","volume":"29","author":"JM van der Burg","year":"2008","unstructured":"van der Burg, J. M. et al. Increased metabolism in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiology of disease 29, 41\u201351, https:\/\/doi.org\/10.1016\/j.nbd.2007.07.029 (2008).","journal-title":"Neurobiology of disease"},{"key":"27121_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13713-5","volume":"7","author":"M Sj\u00f6gren","year":"2017","unstructured":"Sj\u00f6gren, M. et al. Ghrelin rescues skeletal muscle catabolic profile in the R6\/2 mouse model of Huntington\u2019s disease. Scientific reports 7, 13896, https:\/\/doi.org\/10.1038\/s41598-017-13713-5 (2017).","journal-title":"Scientific reports"},{"key":"27121_CR39","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1038\/nutd.2017.17","volume":"7","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Liraglutide reduces body weight by upregulation of adenylate cyclase 3. Nutrition & diabetes 7, e265, https:\/\/doi.org\/10.1038\/nutd.2017.17 (2017).","journal-title":"Nutrition & diabetes"},{"key":"27121_CR40","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1152\/ajpendo.00630.2010","volume":"301","author":"P She","year":"2011","unstructured":"She, P. et al. Molecular characterization of skeletal muscle atrophy in the R6\/2 mouse model of Huntington\u2019s disease. American journal of physiology. Endocrinology and metabolism 301, E49\u201361, https:\/\/doi.org\/10.1152\/ajpendo.00630.2010 (2011).","journal-title":"American journal of physiology. Endocrinology and metabolism"},{"key":"27121_CR41","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","volume":"71","author":"NA Aziz","year":"2008","unstructured":"Aziz, N. A. et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71, 1506\u20131513, https:\/\/doi.org\/10.1212\/01.wnl.0000334276.09729.0e (2008).","journal-title":"Neurology"},{"key":"27121_CR42","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/01.wnl.0000204230.16619.d9","volume":"66","author":"A Rosenblatt","year":"2006","unstructured":"Rosenblatt, A. et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66, 1016\u20131020, https:\/\/doi.org\/10.1212\/01.wnl.0000204230.16619.d9 (2006).","journal-title":"Neurology"},{"key":"27121_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","volume":"25","author":"T Vilsboll","year":"2008","unstructured":"Vilsboll, T. et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association 25, 152\u2013156, https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02333.x (2008).","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"key":"27121_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/002215540405200301","volume":"52","author":"N Wierup","year":"2004","unstructured":"Wierup, N., Yang, S., McEvilly, R. J., Mulder, H. & Sundler, F. Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832\/13) cells. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 52, 301\u2013310 (2004).","journal-title":"The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society"},{"key":"27121_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1210\/endo.143.1.8602","volume":"143","author":"HM Lee","year":"2002","unstructured":"Lee, H. M., Wang, G., Englander, E. W., Kojima, M. & Greeley, G. H. Jr. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143, 185\u2013190, https:\/\/doi.org\/10.1210\/endo.143.1.8602 (2002).","journal-title":"Endocrinology"},{"key":"27121_CR46","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1172\/JCI46305","volume":"121","author":"M Sadagurski","year":"2011","unstructured":"Sadagurski, M. et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. The Journal of clinical investigation 121, 4070\u20134081, https:\/\/doi.org\/10.1172\/JCI46305 (2011).","journal-title":"The Journal of clinical investigation"},{"issue":"Suppl 1","key":"27121_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/dom.12347","volume":"16","author":"MF White","year":"2014","unstructured":"White, M. F. IRS2 integrates insulin\/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes, obesity & metabolism 16(Suppl 1), 4\u201315, https:\/\/doi.org\/10.1111\/dom.12347 (2014).","journal-title":"Diabetes, obesity & metabolism"},{"key":"27121_CR48","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1093\/hmg\/ddv209","volume":"24","author":"J Hamilton","year":"2015","unstructured":"Hamilton, J., Pellman, J. J., Brustovetsky, T., Harris, R. A. & Brustovetsky, N. Oxidative metabolism in YAC128 mouse model of Huntington\u2019s disease. Human molecular genetics 24, 4862\u20134878, https:\/\/doi.org\/10.1093\/hmg\/ddv209 (2015).","journal-title":"Human molecular genetics"},{"key":"27121_CR49","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/jcbfm.2012.104","volume":"32","author":"I Tkac","year":"2012","unstructured":"Tkac, I. et al. Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 32, 1977\u20131988, https:\/\/doi.org\/10.1038\/jcbfm.2012.104 (2012).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"27121_CR50","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","volume":"28","author":"AL Orr","year":"2008","unstructured":"Orr, A. L. et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. The Journal of neuroscience: the official journal of the Society for Neuroscience 28, 2783\u20132792, https:\/\/doi.org\/10.1523\/JNEUROSCI.0106-08.2008 (2008).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"27121_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mds.25009","volume":"27","author":"F Mochel","year":"2012","unstructured":"Mochel, F. et al. Abnormal response to cortical activation in early stages of Huntington disease. Movement disorders: official journal of the Movement Disorder Society 27, 907\u2013910, https:\/\/doi.org\/10.1002\/mds.25009 (2012).","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"27121_CR52","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jcbfm.2011.157","volume":"32","author":"L Zacharoff","year":"2012","unstructured":"Zacharoff, L. et al. Cortical metabolites as biomarkers in the R6\/2 model of Huntington\u2019s disease. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 32, 502\u2013514, https:\/\/doi.org\/10.1038\/jcbfm.2011.157 (2012).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"27121_CR53","doi-asserted-by":"publisher","first-page":"e20934","DOI":"10.1371\/journal.pone.0020934","volume":"6","author":"NK Huang","year":"2011","unstructured":"Huang, N. K. et al. A new drug design targeting the adenosinergic system for Huntington\u2019s disease. PloS one 6, e20934, https:\/\/doi.org\/10.1371\/journal.pone.0020934 (2011).","journal-title":"PloS one"},{"key":"27121_CR54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/hmg\/ddw402","volume":"26","author":"YH Kao","year":"2017","unstructured":"Kao, Y. H. et al. Targeting ENT1 and adenosine tone for the treatment of Huntington\u2019s disease. Human molecular genetics 26, 467\u2013478, https:\/\/doi.org\/10.1093\/hmg\/ddw402 (2017).","journal-title":"Human molecular genetics"},{"key":"27121_CR55","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.7150\/ijbs.9719","volume":"10","author":"H Wu","year":"2014","unstructured":"Wu, H. et al. Caspases: a molecular switch node in the crosstalk between autophagy and apoptosis. International journal of biological sciences 10, 1072\u20131083, https:\/\/doi.org\/10.7150\/ijbs.9719 (2014).","journal-title":"International journal of biological sciences"},{"key":"27121_CR56","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.tins.2011.09.001","volume":"34","author":"RK Graham","year":"2011","unstructured":"Graham, R. K., Ehrnhoefer, D. E. & Hayden, M. R. Caspase-6 and neurodegeneration. Trends in neurosciences 34, 646\u2013656, https:\/\/doi.org\/10.1016\/j.tins.2011.09.001 (2011).","journal-title":"Trends in neurosciences"},{"key":"27121_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nbd.2008.11.015","volume":"33","author":"AJ Morton","year":"2009","unstructured":"Morton, A. J. et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6\/2 mice. Neurobiology of disease 33, 331\u2013341, https:\/\/doi.org\/10.1016\/j.nbd.2008.11.015 (2009).","journal-title":"Neurobiology of disease"},{"key":"27121_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14179-1","volume":"7","author":"R Soylu-Kucharz","year":"2017","unstructured":"Soylu-Kucharz, R. et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington\u2019s disease R6\/2 mice. Scientific reports 7, 14114, https:\/\/doi.org\/10.1038\/s41598-017-14179-1 (2017).","journal-title":"Scientific reports"},{"key":"27121_CR59","doi-asserted-by":"publisher","first-page":"e0153968","DOI":"10.1371\/journal.pone.0153968","volume":"11","author":"E Bianchi","year":"2016","unstructured":"Bianchi, E. et al. Ghrelin Inhibits Post-Operative Adhesions via Blockage of the TGF-beta Signaling Pathway. PloS one 11, e0153968, https:\/\/doi.org\/10.1371\/journal.pone.0153968 (2016).","journal-title":"PloS one"},{"key":"27121_CR60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0003-2697(85)90405-1","volume":"146","author":"V Stocchi","year":"1985","unstructured":"Stocchi, V. et al. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Analytical biochemistry 146, 118\u2013124 (1985).","journal-title":"Analytical biochemistry"},{"key":"27121_CR61","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.1523\/JNEUROSCI.19-18-07860.1999","volume":"19","author":"SP Cregan","year":"1999","unstructured":"Cregan, S. P. et al. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 19, 7860\u20137869 (1999).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"27121_CR62","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.freeradbiomed.2003.08.022","volume":"35","author":"J Gil","year":"2003","unstructured":"Gil, J., Almeida, S., Oliveira, C. R. & Rego, A. C. Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free radical biology & medicine 35, 1500\u20131514 (2003).","journal-title":"Free radical biology & medicine"},{"key":"27121_CR63","doi-asserted-by":"crossref","unstructured":"Gould, T. D. and Kovacsics, C. E. The Open Field Test. Vol. 42 1\u201320 (Humana Press, Totowa, NJ, 2009).","DOI":"10.1007\/978-1-60761-303-9_1"},{"key":"27121_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2005.01.024","volume":"20","author":"MA Hickey","year":"2005","unstructured":"Hickey, M. A., Gallant, K., Gross, G. G., Levine, M. S. & Chesselet, M. F. Early behavioral deficits in R6\/2 mice suitable for use in preclinical drug testing. Neurobiology of disease 20, 1\u201311, https:\/\/doi.org\/10.1016\/j.nbd.2005.01.024 (2005).","journal-title":"Neurobiology of disease"},{"key":"27121_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0006-8993(02)04275-0","volume":"970","author":"O Hansson","year":"2003","unstructured":"Hansson, O. et al. Overexpression of heat shock protein 70 in R6\/2 Huntington\u2019s disease mice has only modest effects on disease progression. Brain research 970, 47\u201357 (2003).","journal-title":"Brain research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27121-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27121-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:23:07Z","timestamp":1671603787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27121-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27121"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27121-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"assertion":[{"value":"30 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8961"}}